Getting by with a little help from the right CD4+ T cells

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Hoepner, Sabine ^a,b   Walker, Paul R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adoptive cell transfer; Brain tumors; Cytotoxic T lymphocytes; Immunotherapy; T helper epitope; TH1 CD4+ T cells; TH2 CD4+ T cells; Tumor associated antigens

Indexed keywords

ALPHA4 INTEGRIN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ARTICLE; BRAIN CANCER; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSPORT; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE HOMING; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; PROTEIN EXPRESSION; TH1 CELL;

EID: 84890252530     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25772     Document Type: Article

References (10)

1. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; http://dx.doi.org/10.1038/nri3191
2. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17:1603-15; http://dx.doi. org/10.1158/1078-0432.CCR-10-2563
3. Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012; 135:1042-54; http://dx.doi.org/10.1093/brain/aws042
4. Lanzavecchia A. Immunology. Licence to kill. Nature 1998; 393:413-4; http://dx.doi.org/10.1038/30845
5. Slingluff CL Jr. The Present and Future of Peptide Vaccines for Cancer: Single or Multiple, Long or Short, Alone or in Combination. Cancer J 2011; 17:343-50; http://dx.doi.org/10.1097/PPO.0b013e318233e5b2
6. Hoepner S, Loh JM, Riccadonna C, Derouazi M, Maroun CY, Dietrich PY, et al. Synergy between CD8 T Cells and Th1 or Th2 Polarised CD4 T Cells for Adoptive Immunotherapy of Brain Tumours. PLoS ONE 2013; 8:e63933; http://dx.doi.org/10.1371/journal. pone.0063933
7. Okada H. Brain tumor immunotherapy with type- 1 polarizing strategies. Ann N Y Acad Sci 2009; 1174:18-23; http://dx.doi.org/10.1111/j.1749-6632.2009.04932.x
8. + TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 2007; 109:4865-76; http://dx.doi.org/10.1182/blood-2006-09-045245
9. + T lymphocytes. Cancer Res 2010; 70:8368-77; http://dx.doi.org/10.1158/0008-5472. CAN-10-1322
10. Dosset M, Vauchy C, Beziaud L, Adotevi O, Godet Y. Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. OncoImmunology 2013; 2:e23430; http://dx.doi.org/10.4161/onci.23430